Group 1 - The core viewpoint of the news is that Hualan Vaccine's stock is currently in a state of decline, having dropped to 20.62 yuan, reflecting a decrease of 2.92% [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share and a total of 40.01 million shares issued [1][2] - On its first trading day, Hualan Vaccine reached a peak price of 79.78 yuan, indicating strong initial market interest [2] Group 2 - The total amount raised from the IPO was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [2] - The funds raised were intended for various projects, including the development and industrialization of flu vaccines, rabies vaccines, multi-component bacterial vaccines, and new pneumonia vaccines, as well as the establishment of a new vaccine research platform [2] - The total issuance costs for the IPO amounted to 31.5657 million yuan, with the lead underwriter, Huatai United Securities, receiving a total of 22 million yuan in underwriting and sponsorship fees [2] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Group 1 - The stock of Hualan Biological Engineering (华兰疫苗) closed at 21.66 yuan, reflecting a decline of 1.10% and is currently in a state of breaking below its initial public offering price [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - The highest price reached on the first day of trading was 79.78 yuan, indicating significant initial market interest [1] Group 2 - The total funds raised from the IPO amounted to 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] - The actual funds raised were 251 million yuan less than the planned 2.495 billion yuan, which was intended for various vaccine development and production projects [1] - The total issuance costs were 31.5657 million yuan, with Huatai United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [1] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution is set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Core Viewpoint - Hualan Vaccine's stock is currently trading at 21.90 yuan, reflecting a decline of 3.48% and is in a state of breaking below its initial public offering price [1] Group 1: IPO and Stock Performance - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial offering price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - On its first trading day, Hualan Vaccine reached an intraday high of 79.78 yuan [2] - The total funds raised from the initial public offering amounted to 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [2] Group 2: Fund Utilization and Financial Details - The funds raised were intended for several projects, including the development and industrialization of flu vaccines, rabies vaccines, multi-component bacterial vaccines, and new pneumonia vaccines, as well as the establishment of a new vaccine research platform [2] - The total issuance costs for the IPO were 31.5657 million yuan, with Huatian United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [2] Group 3: Dividend Distribution - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares held and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for this equity distribution is set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Core Viewpoint - Hualan Vaccine's stock has fallen to 22.62 yuan, marking a decline of 9.05% and is currently in a state of breaking below its initial public offering price [1] Group 1: IPO and Stock Performance - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial offering price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - On its first trading day, Hualan Vaccine reached a peak price of 79.78 yuan, indicating strong initial market interest [2] - The total funds raised from the IPO amounted to 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [2] Group 2: Fund Utilization and Financial Details - The funds raised were intended for several projects, including the development and industrialization of flu vaccines, rabies vaccines, multi-component bacterial vaccines, and new pneumonia vaccines, as well as the establishment of a new vaccine research platform [2] - The total issuance costs for the IPO were 31.5657 million yuan, with Huatian United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [2] Group 3: Dividend Distribution - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which included a cash dividend of 3.00 yuan for every 10 shares held and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for this equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Group 1 - The core point of the article is that Hualan Vaccine (301207.SZ) is currently trading at 19.14 yuan, reflecting a decline of 2.30% and is in a state of breaking its initial public offering price [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share and a total of 40.01 million shares issued [1][2] - On its first trading day, Hualan Vaccine reached a peak price of 79.78 yuan, indicating strong initial market interest [2] Group 2 - The total amount raised from the IPO was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [2] - The company planned to raise 2.495 billion yuan, which was 251 million yuan less than the actual amount raised, for various vaccine development and production projects [2] - The annual equity distribution plan for 2022 includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 5 shares for every 10 shares, with key dates for registration and ex-dividend set for June 6 and June 7, 2023, respectively [2]

Group 1 - The stock of Hualan Biological Engineering (华兰疫苗) closed at 20.29 yuan, reflecting a decline of 3.38%, and is currently in a state of below its initial public offering (IPO) price [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 18, 2022, with an IPO price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - The total funds raised from the IPO amounted to 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] Group 2 - In 2022, Hualan Vaccine announced a dividend distribution plan, proposing a cash dividend of 3.00 yuan for every 10 shares held, along with a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the dividend distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Core Viewpoint - The announcement from the China Securities Index Co., Ltd. regarding the adjustment of sample stocks for various indices, including the Shenzhen Component Index and ChiNext Index, indicates that Hualan Biological Engineering Inc. (华兰疫苗) will be removed from the Shenzhen Component Index as of December 15, 2025 [1] Group 1: Company Overview - Hualan Biological Engineering Inc. was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering (IPO) of 40.01 million shares at a price of 56.88 RMB per share [2] - The stock reached a peak of 79.78 RMB on its first trading day but is currently trading below its IPO price, indicating a state of loss [2] - The total funds raised from the IPO amounted to 2.276 billion RMB, with a net amount of 2.244 billion RMB after deducting issuance costs [2][3] Group 2: Financial Performance - The company initially planned to raise 2.495 billion RMB, but the actual amount raised was 251 million RMB less than expected [2] - Hualan Biological's 2022 annual equity distribution plan included a cash dividend of 3.00 RMB per 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [3][4] - The company has a registered capital of 601.0275 million RMB and paid-in capital of 360 million RMB [4]

Core Points - Hualan Vaccine's stock closed at 23.07 yuan, down 6.60%, with a total market capitalization of 13.866 billion yuan, currently in a state of decline [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share [1] - On the first day of trading, Hualan Vaccine reached an intraday high of 79.78 yuan [1] - The total funds raised from the IPO amounted to 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] - The actual funds raised were 251 million yuan less than the planned 2.495 billion yuan, which was intended for various vaccine development and production projects [1] - The total issuance costs for the IPO were 31.5657 million yuan, with the underwriter, Huatai United Securities, receiving a total of 22 million yuan in underwriting and sponsorship fees [1] Dividend Announcement - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Group 1 - The core point of the news is that Hualan Vaccine's stock is currently trading at 24.01 yuan, reflecting a decline of 5.40% and is in a state of breaking its initial public offering price [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - The stock reached its highest point of 79.78 yuan on the first day of trading but has since experienced a downward trend [1] Group 2 - The total amount raised from the initial public offering was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] - The actual funds raised were 251 million yuan less than the planned amount of 2.495 billion yuan, which was intended for various vaccine development and production projects [1] - The total issuance costs amounted to 31.5657 million yuan, with Huatai United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [1] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Core Points - Hualan Vaccine's stock closed at 19.55 yuan, down 2.98%, currently in a broken state [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share [1][2] - The total amount raised from the IPO was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs [2] Fundraising and Projects - The company initially planned to raise 2.495 billion yuan, with funds allocated for various vaccine development projects, including influenza, rabies, and pneumonia vaccines [2] - The total issuance costs amounted to 31.5657 million yuan, with the underwriter, Huatai United Securities, receiving 22 million yuan in underwriting and sponsorship fees [2] Dividend Distribution - On May 30, 2023, Hualan Vaccine announced a dividend distribution plan for 2022, proposing a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 5 shares for every 10 shares [2]